Peptides in 2026, What the FDA Review Means Olympia Pharmaceuticals FDA Peptide Reclassification 2026: What Researchers Want FDA Peptide Category 2 Removal & Public Meeting July 23rd Mansi Hukmani posted on the topic LinkedIn BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what